Should ARB/CAB combination tablets be continued or withheld preoperatively?

A multicenter single-blind randomized study to compare effects of continuing and withholding angiotensin receptor blocker(ARB)-calcium blocker (CAB) combination tablets before surgery on perioperative hemodynamics in patients undergoing non-cardiac surgery - Effects of continuing vs withholding ARB/CAB combination tablets before surgery on perioperative hemodynamics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031190027

Enrollment

120

Registered

2019-05-22

Start date

2019-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension under treatment with ARB/CAB combination tablets hypertension, general anesthesia

Interventions

Randomization into continuing and withholding ARB/CAB combination tablets before general anesthesia and surgery

Randomization into two groups

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Surgical patients with hypertension treated with ARB/CAB combination tablets

Exclusion criteria

Exclusion criteria: Patients having severe comorbidities, including heart disease, and those scheduled for major surgery including cardiac surgery

Design outcomes

Primary

Measure	Time frame
Perioperative changes in blood pressure and requirements of vasoactive agents	—

Secondary

Measure	Time frame
Incidences of perioperative complications, including profound hypotension, profound hypertension, and electrocardiographic abnormalities	—

Contacts

Public ContactMasakazu Hayashida

Juntendo University Hospital

hayashidatoday@yahoo.co.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026